Tom Verhaeghe

2.0k citations

76 papers · 1.4k indexed · h-index 24

Biotechnology top 2%
- Enzyme Production and Characterization 8
Pharmacology top 5%
- Alkaloids: synthesis and pharmacology 7
- Cholinesterase and Neurodegenerative Diseases 7
Pharmacology top 5%
- Alkaloids: synthesis and pharmacology 7
- Cholinesterase and Neurodegenerative Diseases 7
Nutrition and Dietetics top 10%
Molecular Biology
- Glycosylation and Glycoproteins Research 6
Immunology
- Biosimilars and Bioanalytical Methods 13
Organic Chemistry
- Chemical synthesis and alkaloids 11
Pediatrics, Perinatology and Child Health
- Pharmacological Effects and Toxicity Studies 8
Psychiatry and Mental health
- Epilepsy research and treatment 7

Co-authors: Tom Desmet Wim Soetaert Dirk Aerts Lieve Dillen Karel De Winter Ronald de Vries Philip Timmerman Qinying Zhao
Cited by: Biotechnology Pharmacology
Journals: Journal of Biological Chemistry (1 paper)Angewandte Chemie International Edition (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations: Belgium United States Switzerland

In The Last Decade

Tom Verhaeghe

74 papers receiving 1.4k citations

Peers

Countries citing papers authored by Tom Verhaeghe

Since Specialization

Citations

This map shows the geographic impact of Tom Verhaeghe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Verhaeghe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Verhaeghe more than expected).

Fields of papers citing papers by Tom Verhaeghe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Verhaeghe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Verhaeghe. The network helps show where Tom Verhaeghe may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tom Verhaeghe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tom Verhaeghe Line = papers co-authored together Tom Verhaeghe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Feedback from a workshop by the European Bioanalysis Forum on assay validation requirements for in vitro assays following the publication of ICH M12 guideline – a plea for context-of-use over ICH M10 standards Bioanalysis ·Philip Timmerman,Steve White,Neil Adcock,Cecilia Arfvidsson,Matthew Barfield,Kyra J. Cowan,Luca Ferrari,Michaela Golob,Lee Goodwin,Richard Hughes,Tsvetelina Ivanova,Anna Laurén,Stuart McDougall,Robert M. Nelson,Nico van de Merbel,Tom Verhaeghe,Michael E. Wright	2025	0
2	Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment Nucleic Acid Therapeutics ·Rui Xu,Emmanuel Njumbe Ediage,Tom Verhaeghe,Jan Snoeys,Lieve Dillen	2024	3
3	Multimodal biomarker discovery for active Onchocerca volvulus infection PLoS neglected tropical diseases ·Ole Lagatie,Emmanuel Njumbe Ediage,Dirk Van Roosbroeck,Stijn Van Asten,Ann Verheyen,Linda Batsa Debrah,Alexander Yaw Debrah,Maurice R. Odiere,Ruben t’Kindt,Emmie Dumont,Koen Sandra,Lieve Dillen,Tom Verhaeghe,Rob J. Vreeken,Filip Cuyckens,Lieven Stuyver	2021	5
4	RF plasma simulations using the TOMATOR 1D code: a case study for TCV helium ECRH plasmas Plasma Physics and Controlled Fusion ·T. Wauters,J. Buermans,Rob Haelterman,V.Е. Moiseenko,D. Ricci,Tom Verhaeghe,S. Coda,D. Douai,A. Hakola,A. Lyssoivan,D. Van Eester,(unknown),(unknown)	2020	5
5	Determination of tapentadol and tapentadol-O-glucuronide in human serum samples by UPLC–MS/MS Journal of Chromatography B ·Vera Hillewaert,Klaus Pusecker,Luc Sips,Tom Verhaeghe,Ronald de Vries,Manfred Langhans,Rolf Terlinden,Philip Timmerman	2015	15
6	Creating Space for Large Acceptors: Rational Biocatalyst Design for Resveratrol Glycosylation in an Aqueous System Angewandte Chemie International Edition ·Mareike E. Dirks‐Hofmeister,Tom Verhaeghe,Karel De Winter,Tom Desmet	2015	38
7	A structural classification of carbohydrate epimerases: From mechanistic insights to practical applications Biotechnology Advances ·Stevie Van Overtveldt,Tom Verhaeghe,Henk‐Jan Joosten,Tom van den Bergh,Koen Beerens,Tom Desmet	2015	43
8	Determination of simeprevir: A novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography–tandem mass spectrometry Journal of Chromatography B ·I. Vanwelkenhuysen,Ronald de Vries,Philip Timmerman,Tom Verhaeghe	2014	35
9	Engineering the carbohydrate-binding site of Epa1p from Candida glabrata: generation of adhesin mutants with different carbohydrate specificity Glycobiology ·Francesco Ielasi,Tom Verhaeghe,Tom Desmet,Ronnie Willaert	2014	12
10	Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A Chemical Communications ·Rob De Vreese,Tom Verhaeghe,Tom Desmet,Matthias D’hooghe	2013	31
11	Transglucosylation potential of six sucrose phosphorylases toward different classes of acceptors Carbohydrate Research ·Dirk Aerts,Tom Verhaeghe,Bart I. Roman,Christian V. Stevens,Tom Desmet,Wim Soetaert	2011	54
12	Pharmacokinetics of carisbamate (RWJ‐333369) in healthy Japanese and Western subjects Epilepsia ·Peter Zannikos,Gerald Novak,Caiping Yao,Tom Verhaeghe,Monique Franc,Bhavna Solanki,Meir Bialer	2009	3
13	Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib Cancer Chemotherapy and Pharmacology ·Alex Hemeryck,R Geerts,Johan Monbaliu,Stephan Hassler,Tom Verhaeghe,Luc Diels,Willy Verluyten,Ludy van Beijsterveldt,Rao N. V. S. Mamidi,Cor Janssen,R. De Coster	2007	42
14	An Interaction Study Between the New Antiepileptic and CNS Drug Carisbamate (RWJ‐333369) and Lamotrigine and Valproic Acid Epilepsia ·Shuchean Chien,Caiping Yao,Annemie Mertens,Tom Verhaeghe,Bhavna Solanki,Dennis R. Doose,Gerald Novak,Meir Bialer	2007	19
15	The Absorption, Metabolism, and Excretion of the Novel Neuromodulator RWJ-333369 (1,2-Ethanediol, [1-2-Chlorophenyl]-, 2-carbamate, [ S ]-) in Humans Drug Metabolism and Disposition ·Geert Mannens,Jan Hendrickx,C. G. M. JANSSEN,Shuchean Chien,Bart van Hoof,Tom Verhaeghe,Mark Kao,Michael F. Kelley,Ivo Goris,Mark Bockx,B. Verreet,Meir Bialer,W. Meuldermans	2006	35
16	Steady‐State Pharmacokinetics of Galantamine Are Not Affected by Addition of Memantine in Healthy Subjects The Journal of Clinical Pharmacology ·Caiping Yao,Arash Raoufinia,Michael Gold,Jeffrey S. Nye,Steven Ramael,Mukund Padmanabhan,Yolande Walschap,Tom Verhaeghe,Qinying Zhao	2005	24
17	Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer Cancer Chemotherapy and Pharmacology ·Steven J. Cohen,James M. Gallo,Nancy Lewis,R. Katherine Alpaugh,Louis Gentner,Andr� Rogatko,Gwen Yeslow,Jessie Schol,Tom Verhaeghe,Peter Zannikos,Peter Palmer,Louis M. Weiner,Neal J. Meropol	2004	7
18	Development and validation of a liquid chromatographic–tandem mass spectrometric method for the determination of galantamine in human heparinised plasma Journal of Chromatography B ·Tom Verhaeghe,Luc Diels,Ronald de Vries,Marc De Meulder,Jan de Jong	2003	36
19	Galantamine Pharmacokinetics, Safety, and Tolerability Profiles Are Similar in Healthy Caucasian and Japanese Subjects The Journal of Clinical Pharmacology ·Qinying Zhao,Martin Brett,Nancy Van Osselaer,Huang Feng-lei,A. Raoult,Achiel Van Peer,Tom Verhaeghe,Rita Hust	2002	9
20	Pharmacokinetic and Safety Assessments of Galantamine and Risperidone after the Two Drugs Are Administered Alone and Together The Journal of Clinical Pharmacology ·Fenglei Huang,Kenneth C. Lasseter,Luc Janssens,Tom Verhaeghe,Henry Lau,Qinying Zhao	2002	16

About Tom Verhaeghe

Tom Verhaeghe is a scholar working on Biotechnology, Pharmacology and Immunology, having authored 76 papers that have together received 1.4k indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (13 papers), Chemical synthesis and alkaloids (11 papers), Pharmacological Effects and Toxicity Studies (8 papers), Enzyme Production and Characterization (8 papers), Alkaloids: synthesis and pharmacology (7 papers), Epilepsy research and treatment (7 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Glycosylation and Glycoproteins Research (6 papers). The work is most often cited by research in Biotechnology (213 citations), Pharmacology (235 citations) and Pharmacology (109 citations). Tom Verhaeghe has collaborated with scholars based in Belgium, United States and Switzerland. Frequent co-authors include Tom Desmet, Wim Soetaert, Dirk Aerts, Lieve Dillen, Karel De Winter, Ronald de Vries, Philip Timmerman, Qinying Zhao, Matthias D’hooghe and Rob De Vreese. Their work appears in journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact